Xias Bio

About Xias Bio

Xias Bio Limited, founded in Glasgow, Scotland, in 2020, designs and engineers multifunctional recombinant proteins to replace animal-derived proteins across various industries. The founders, Dr. David Harvey (CEO), Dr. Faadil Fawzy (CSO), and Alister Minty (Chair), combined their more than 20 years of experience in protein design to address the ethical and environmental issues associated with traditional protein sources. The company was incorporated on March 11, 2020.

The company operates on a licensing business model, which allows it to remain capital-efficient. Xias Bio develops bespoke proteins and then licenses the rights to manufacture and use these proteins to its customers, which simplifies formulations and reduces costs for them. The primary market is the cosmetics and personal care industry, where there is high demand for sustainable alternatives to ingredients like collagen, keratin, and elastin. However, the company is also targeting expansion into life sciences, agricultural technology, and cell culture.

The core of Xias Bio's technology is its LiteProtein™ platform, which creates specialized, chimeric proteins by integrating multiple functional motifs into a single molecule. This allows a single Xias Bio protein to perform the functions of several traditional ingredients. The platform has a library of over 2.6 million proteins, all producible through a standard fermentation process. Specific products include ElastiLite™, for cosmetics, and CollaLite™, a collagen-based protein. The company participated in the SOSV IndieBio program in New York, which helped accelerate its growth. It has secured funding from investors including IndieBio, SOSV, and Happiness Capital.